Skip to main content
Premium Trial:

Request an Annual Quote

Seattle's Accelerator Adds PPD as Investor

NEW YORK (GenomeWeb News) – Seattle-based biotechnology investment and management company Accelerator Corporation said today that drug discovery contract research organization PPD has joined as the sixth investor in its Accelerator III investment vehicle.
Accelerator provides resources to biotech companies, including capital financing, facilities, scientific and technical expertise and support, as well as business management and support.
The company did not disclose the value of PPD’s investment, but said that the committment brings total investment in Accelerator III to more than $27 million. 
Accelerator’s life sciences partners include the Institute for Systems Biology, Amgen Ventures, Arch Venture Partners, OVP Venture Partners, Alexandria Real Estate Equities, and WRF Capital.
Accelerator is currently involved in managing three startups, including Seredigm, Recodagen, and Mirina, and the company said that it has facilitated investment and managed nine early-stage companies in the past five years.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.